Stockscreener 앱 받기
2.13
2.29%
-0.05
Aytu Biopharma Inc 주식(AYTU)의 최신 뉴스
Is Aytu BioPharma Inc. a strong candidate for buy and hold2025 Macro Impact & Short-Term High Return Ideas - mfd.ru
How Aytu BioPharma Inc. (AY20) stock gains from tech spendingGlobal Markets & Advanced Technical Analysis Signals - mfd.ru
Will Aytu BioPharma Inc. outperform tech stocksShare Buyback & Smart Allocation Stock Tips - mfd.ru
Will Aytu BioPharma Inc. benefit from rising consumer demandJuly 2025 Drop Watch & High Accuracy Swing Entry Alerts - mfd.ru
Lake Street Remains a Buy on Aytu BioScience (AYTU) - The Globe and Mail
Aytu BioPharma Insider Buyers Net US$87k Despite 10% Stock Decline - simplywall.st
Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Shift From Loss To Profit - Yahoo Finance
Aytu BioPharma Q2 Earnings Call Highlights - Defense World
Aytu BioPharma AYTU Q2 2026 Earnings Transcript - AOL.com
Full Transcript: Aytu BioPharma Q2 2026 Earnings Call - Benzinga
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q2 2026 Earnings Call Transcript - Insider Monkey
Aytu BioPharma Inc (AYTU) Q2 2026 Earnings Call Highlights: Navi - GuruFocus
Earnings call transcript: Aytu BioPharma Q2 2026 sees revenue dip, stock falls - Investing.com Nigeria
Aytu BioPharma Inc (NASDAQ:AYTU) Posts Q2 Revenue Beat Amid EXXUA Launch Costs - ChartMill
AYTU: Exxua launch drives early momentum; net revenue $15.2M, net loss $10.6M on launch costs - TradingView
Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
AYTU Reports Q2 Revenue Decline Amid Shift to New Product Launch - GuruFocus
Aytu BioPharma Q2 Earnings Summary & Key Takeaways - Benzinga
Aytu BioPharma Q2 Earnings Assessment - Benzinga
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results - ACCESS Newswire
Aytu BioPharma Q2 revenue beats expectations - TradingView
Earnings To Watch: Aytu BioPharma Inc (AYTU) Reports Q2 2026 Res - GuruFocus
New Strong Sell Stocks for February 2nd - Nasdaq
Earnings Recap: Is Aytu BioPharma Inc stock influenced by commodity pricesProduct Launch & Weekly Market Pulse Alerts - baoquankhu1.vn
Gainers Report: Will Aytu BioPharma Inc stock benefit from M A2025 Momentum Check & Safe Entry Point Identification - baoquankhu1.vn
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026 - ACCESS Newswire
Pharma News: Will Aytu BioPharma Inc benefit from rising consumer demandQuarterly Market Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
Aytu launches EXXUA, first selective 5-HT1A agonist for depression By Investing.com - Investing.com South Africa
Aytu BioPharma Highlights EXXUA Opportunity at Investor Day - TipRanks
Aytu BioPharma Recaps Investor Day Held on January 20, 2026 - ACCESS Newswire
Aytu BioPharma Recaps Investor Day and EXXUA Launch - TradingView
New EXXUA depression drug targets MDD without sexual side effects - Stock Titan
AYTU: Exxua launches as a differentiated MDD therapy, targeting growth with disciplined, scalable execution - TradingView
AYTU: Exxua launches as a novel MDD therapy, targeting unmet needs with strong financial discipline - TradingView
Aytu launches EXXUA, first selective 5-HT1A agonist for depression - Investing.com
Aytu BioPharma (AYTU) Launches EXXUA for Treating Major Depressi - GuruFocus
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Di - PharmiWeb.com
Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA - ACCESS Newswire
New depression drug EXXUA avoids sexual dysfunction and weight gain - Stock Titan
Will Aytu BioPharma Inc. (AY20) stock outperform global peersREITs Market Trends & Small Investment Big Gains - Bollywood Helpline
Aytu BioPharma Talks Exxua MDD Launch, Differentiation and RxConnect Access at Investor Summit - Defense World
AYTU: Exxua's launch leverages unique differentiation and RxConnect to target major growth in depression treatment - TradingView — Track All Markets
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026 - 富途牛牛
Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City - ACCESS Newswire
How Aytu BioPharma Inc. (AY20) stock reacts to fiscal policiesJuly 2025 Technicals & Stepwise Swing Trade Plans - ulpravda.ru
Buybacks Report: Is Aytu BioPharma Inc. stock dividend yield sustainableForecast Cut & Daily Volume Surge Signals - Улправда
Portfolio Recap: How sustainable is Aytu BioPharma Inc. stock dividend payoutQuarterly Market Summary & AI Enhanced Trading Alerts - Улправда
Why Aytu BioPharma Inc. stock attracts high net worth investorsMarket Risk Report & High Accuracy Trade Alerts - Улправда
1.19%
0.83%
자본화:
|
볼륨(24시간):